MEGAN SLOAN: Open Payments
NPI 1639425499 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$656 in 31 payments from 10 companies in 2025. Trend: 2023 $208 · 2024 $780 · 2025 $656
Food & beverage: $656
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 11 | $257 |
| Otsuka America Pharmaceutical, Inc. | 5 | $95 |
| Neurocrine BioSciences, Inc. | 4 | $79 |
| Lundbeck LLC | 3 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| ABBVIE INC. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
Products named: Auvelity, REXULTI, INGREZZA, CAPLYTA, TRINTELLIX, FANAPT, AUSTEDO XR, VRAYLAR.
Industry payments across WI — which companies pay providers there.
